Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models

Key Result

Bemnifosbuvir inhibits hepatitis E virus replication in preclinical models and has a favorable safety profile, supporting trials in chronic HEV patients.

Key Points

• The aim is to evaluate the efficacy of bemnifosbuvir in inhibiting hepatitis E virus replication.
• Utilized preclinical models to study the effect of bemnifosbuvir on hepatitis E virus.
• Monitored viral replication levels post-treatment.
• Assessed safety profile alongside antiviral efficacy.
• Bemnifosbuvir effectively inhibits hepatitis E virus replication in vitro and in preclinical models.
• Safety profile appears favourable, indicating potential for patient trials.